Literature DB >> 17151363

Exploring the uses of RNAi--gene knockdown and the Nobel Prize.

René Bernards1.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 17151363     DOI： 10.1056/NEJMp068242

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

1.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

2.  Passing the baton--to whom?

Authors:  Aldo A Rossini
Journal:  J Clin Invest       Date:  2007-02       Impact factor: 14.808

Review 3.  Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?

Authors:  Dirk Grimm; Mark A Kay
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 4.  PCSK9: From Basic Science Discoveries to Clinical Trials.

Authors:  Michael D Shapiro; Hagai Tavori; Sergio Fazio
Journal:  Circ Res       Date:  2018-05-11       Impact factor: 17.367

Review 5.  Therapeutic potential of chemically modified siRNA: Recent trends.

Authors:  Chelliah Selvam; Daniel Mutisya; Sandhya Prakash; Kasturi Ranganna; Ramasamy Thilagavathi
Journal:  Chem Biol Drug Des       Date:  2017-05-16       Impact factor: 2.817

Review 6.  Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.

Authors:  Marja-Riitta Taskinen; Chris J Packard; Jan Borén
Journal:  Curr Atheroscler Rep       Date:  2019-05-20       Impact factor: 5.113

Review 7.  Novel therapeutic targets and agents for pediatric dyslipidemia.

Authors:  Bhuvana Sunil; Christy Foster; Don P Wilson; Ambika P Ashraf
Journal:  Ther Adv Endocrinol Metab       Date:  2021-11-24       Impact factor: 3.565

Review 8.  The promising novel therapies for familial hypercholesterolemia.

Authors:  Ruoyu Chen; Shaoyi Lin; Xiaomin Chen
Journal:  J Clin Lab Anal       Date:  2022-06-17       Impact factor: 3.124

Review 9.  Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.

Authors:  Constantine E Kosmas; Alba Muñoz Estrella; Andreas Sourlas; Delia Silverio; Elizabeth Hilario; Peter D Montan; Eliscer Guzman
Journal:  Diseases       Date:  2018-07-13

Review 10.  Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran).

Authors:  David Sinning; Ulf Landmesser
Journal:  Curr Cardiol Rep       Date:  2020-10-21       Impact factor: 2.931
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.